Big Pharma Ditches Antibiotic Research When It’s Needed Most

Every year, antibiotic resistance claims 700,000 lives. Where are the new drugs?

Julien Behal/PA Wire via ZUMA

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.

Every year, at least 2 million Americans get infected with bacteria that have evolved  to resist antibiotics, and at least 23,000 people die. Globally, resistant pathogens take 700,000 lives annually. Given this level of disease and death, you might think Big Pharma would be scrambling to come up with new antibiotics to cash in on the rising tide of resistance. 

Think again. Last year, the World Health Organization warned that the pipeline of new drugs is “insufficient to mitigate the threat of antimicrobial resistance.” On Wednesday, the Swiss pharmaceutical giant Novartis announced it was shuttering its research efforts to discover new antibiotics, reports Endpoints News, a website that tracks R&D in the pharma and biotech industry. 

In bailing on antibiotics, Novartis is following the lead of its Big Pharma peers, which have largely abandoned the search for new compounds to fight bacterial infections. The reason is related to profits. The most lucrative drugs target lingering conditions like rheumatoid arthritis and other autoimmune disorders. Doctors tend to prescribe antibiotics for relatively short period—meaning less sales for drug companies. Worse, unlike, say, a drug to treat high blood pressure, antibiotics are fragile—the more antibiotics are used, the more opportunity bacteria have to develop resistance, rendering the treatment ineffective.

No wonder that, in its 2017 report on the new antibiotics in development globally, the World Health Organization is so pessimistic. Most of the drugs in the pipeline are “modifications of existing antibiotic classes,” the WHO lamented, “They are only short term solutions as they usually cannot overcome multiple existing resistance mechanisms and do not control the growing number of pan-resistant pathogens.” Some novel non-antibiotic treatments that have shown promise in fighting stubborn infections, but they face regulatory hurdles, as Maryn McKenna explains in this recent Mother Jones feature.

Meanwhile, the US meat industry continues to be a massive user of antibiotics—including ones that are vital for human medicine. In a June 2018 report, the Natural Resources Defense Council found that “roughly 27.1 percent of medically important antibiotics are sold for pork production, compared to 27.6 percent sold for treating humans.”

And in a recent analysis of more than 47,000 federal government lab tests of bacteria on supermarket meat, Environmental Working Group found antibiotic resistant bacteria on 79 percent of ground turkey, 71 percent of pork chops, 62 percent of ground beef, and 36 percent of chicken parts. Learn how to properly wash your hands while cooking, people. 

IT'S NOT THAT WE'RE SCREWED WITHOUT TRUMP:

"It's that we're screwed with or without him if we can't show the public that what we do matters for the long term," writes Mother Jones CEO Monika Bauerlein as she kicks off our drive to raise $350,000 in donations from readers by July 17.

This is a big one for us. It's our first time asking for an outpouring of support since screams of FAKE NEWS and so much of what Trump stood for made everything we do so visceral. Like most newsrooms, we face incredibly hard budget realities, and it's unnerving needing to raise big money when traffic is down.

So, as we ask you to consider supporting our team's journalism, we thought we'd slow down and check in about where Mother Jones is and where we're going after the chaotic last several years. This comparatively slow moment is also an urgent one for Mother Jones: You can read more in "Slow News Is Good News," and if you're able to, please support our team's hard-hitting journalism and help us reach our big $350,000 goal with a donation today.

payment methods

IT'S NOT THAT WE'RE SCREWED WITHOUT TRUMP:

"It's that we're screwed with or without him if we can't show the public that what we do matters for the long term," writes Mother Jones CEO Monika Bauerlein as she kicks off our drive to raise $350,000 in donations from readers by July 17.

This is a big one for us. So, as we ask you to consider supporting our team's journalism, we thought we'd slow down and check in about where Mother Jones is and where we're going after the chaotic last several years. This comparatively slow moment is also an urgent one for Mother Jones: You can read more in "Slow News Is Good News," and if you're able to, please support our team's hard-hitting journalism and help us reach our big $350,000 goal with a donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate